Tue Wenzel Kragstrup

Tue Wenzel Kragstrup

Auto-generated profile, based on publicly available information

Tue Wenzel Kragstrup

Department of Biomedicine Aarhus University Aarhus Denmark

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LGLaure Gossec
Laure Gossec
XBXenofon Baraliakos
Xenofon Baraliakos
AKAndreas Kerschbaumer
Andreas Kerschbaumer
MWMaarten de Wit
Maarten de Wit
IMIain McInnes
Iain McInnes
JSJosef S Smolen
Josef S Smolen
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined. Results The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed. Conclusion These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.

18 August 2011 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
PDF file
TKT. W. Kragstrup
T. W. Kragstrup
MKM. Kjaer
M. Kjaer
AMAbigail Mackey
Abigail Mackey

12 October 2016 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
MAMorten N. Andersen
Morten N. Andersen
SASinan N. H. Al‐Karradi
Sinan N. H. Al‐Karradi
TKTue W. Kragstrup
Tue W. Kragstrup
MHMarianne Hokland
Marianne Hokland

4 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTue W. Kragstrup
Tue W. Kragstrup
HSHelene Søgaard Singh
Helene Søgaard Singh
IGIda Grundberg
Ida Grundberg
ANAne Langkilde-Lauesen Nielsen
Ane Langkilde-Lauesen Nielsen
FRFelice Rivellese
Felice Rivellese
BBBo Martin Bibby
Bo Martin Bibby
Aims: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the infection termed coronavirus disease of 2019 (COVID-19). Here, we investigate associations between plasma ACE2 and outcome of COVID-19. Methods and results: This analysis used data from a large longitudinal study of 306 COVID-19 positive patients and 78 COVID-19 negative patients (MGH Emergency Department COVID-19 Cohort). Comprehensive clinical data were collected on this cohort, including 28-day outcomes. The samples were run on the Olink® Explore 1536 platform which includes measurement of the ACE2 protein. High admission plasma ACE2 in COVID-19 patients was associated with increased maximal illness severity within 28 days with OR = 1.8, 95%-CI: 1.4–2.3 (P < 0.0001). Plasma ACE2 was significantly higher in COVID-19 patients with hypertension compared with patients without hypertension (P = 0.0045). Circulating ACE2 was also significantly higher in COVID-19 patients with pre-existing heart conditions and kidney disease compared with patients without these pre-existing conditions (P = 0.0363 and P = 0.0303, respectively). Conclusion: This study suggests that measuring plasma ACE2 is potentially valuable in predicting COVID-19 outcomes. Further, ACE2 could be a link between COVID-19 illness severity and its established risk factors hypertension, pre-existing heart disease and pre-existing kidney disease.

1 January 2008 in Cytokine
Verified
Journal Article
Closed access
TKTue Wenzel Kragstrup
Tue Wenzel Kragstrup
KOKristian Otkjaer
Kristian Otkjaer
CHChristian Kanstrup Holm
Christian Kanstrup Holm
AJAnnette Jørgensen
Annette Jørgensen
MHMarianne Hokland
Marianne Hokland
BDBent Deleuran
Bent Deleuran

23 February 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
TKTue Wenzel Kragstrup
Tue Wenzel Kragstrup
BGBente Glintborg
Bente Glintborg
ASAnnemarie L Svensson
Annemarie L Svensson
CMChristopher McMaster
Christopher McMaster
PRPhilip C Robinson
Philip C Robinson
DLDavid Liew
David Liew
The US Food and Drug Administration (FDA) has recently added a new ‘black box warning’ on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour necrosis factor alpha inhibitors in rheumatoid arthritis. This is a warning difficult to ignore because the data, being from a randomised controlled trial, are of high fidelity and hard to reproach. It is especially problematic because safety data for all the other JAK inhibitors will be pending for several years. So how might we proceed, without being bound by our stasis? The lack of absolute certainty seems to require a pragmatic approach to the routine care use of JAK inhibitors. The patients who were at greatest risk were older and had other risk factors for the corresponding adverse events, in keeping with effect modification. This highlights the need to focus on risk stratification when tailoring therapy. In this viewpoint, we propose a simple illustration to guide clinical decision-making. First, identify general risk factors for venous thromboembolic event (VTE), major adverse cardiac event (MACE) and cancer (age>65 years and smoking) and whether there is a previous history of VTE, MACE or cancer. Then, evaluate risk based on the number of other risk factors for VTE and the number of other risk factors for MACE. Ultimately, ‘treat-to-target’ will in the end always be ‘treat-to-agreement’. As we have done in the past, and will do in the future, the optimal treatment strategy will have to be tailored based on individual patient risk factors and preferences in a shared-decision process.